Clinical Trial Update: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Terminated Phase 1/2 trial comparing PF-05212384 plus FOLFIRI to Bevacizumab plus FOLFIRI in metastatic colorectal cancer; results were posted in 2016-08-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• PF-05212384

Snippet

Sponsor: Pfizer | Conditions: Metastatic Colorectal Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-08-18